Atezolizumab Makes Inroads in Non–Small Cell Lung Cancer
Single-agent atezolizumab (formerly MPDL3280A) had excellent clinical activity in both chemotherapy-naïve and previously treated patients with metastatic non–small cell lung cancer (NSCLC) in the phase II FIR study,